盐酸埃克替尼治疗晚期非小细胞肺癌的疗效分析

Analysis of the Efficacy of Icotinib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer

目的探讨晚期非小细胞肺癌患者实施盐酸埃克替尼治疗的疗效。方法抽取2018年6月—2019年6月在该院接受治疗的晚期非小细胞肺癌患者78例为研究对象,根据其住院先后顺序从1~78编号,再按等差数列首项为1,公差为2的方式将78例患者平均分为两组,即对照组与实验组,两组患者均为39例。对照组行晚期恶性肿瘤支持治疗,实验组在对照组基础上行盐酸埃克替尼治疗,对比两组治疗效果及治疗后功能状态恢复情况、治疗安全性及两组患者生存期情况。结果治疗后实验组患者KPS评分(76.9±2.7)分高于对照组(43.5±6.8)分,差异有统计学意义(t=25.400,P<0.05);实验组治疗有效率(30.76%)、病情控制率(84.61%)均高于对照组(12.82%,51.28%),差异有统计学意义(χ^2=4.875、9.704,P<0.05);对照组患者发热、皮疹、消化道症状、转氨酶升高不良症状发生率与实验组无明显区别,差异无统计学意义(χ^2=0.425、0.245、0.487、0.787,P>0.05);实验组患者无进展生存期(7.2±0.5)月、总生存期(10.5±0.7)月均长于对照组,差异有统计学意义(t=8.345、7.678,P<0.05)。结论盐酸埃克替尼在治疗晚期非小细胞肺癌中有重要作用,能够提高患者的KSP评分,提高治疗有效率,有效控制患者的病情,同时治疗安全性也比较高,治疗后患者的生存期变长。

Objective To investigate the therapeutic effect of icotinib hydrochloride in patients with advanced non-small cell lung cancer.Methods A total of 78 patients with advanced non-small cell lung cancer who were treated in the hospital from June 2018 to June 2019 were selected as the research objects.They were numbered from 1-78 according to their hospitalization sequence,and the first item in the arithmetic sequence was 1.With a tolerance of 2,78 patients were equally divided into two groups,the control group and the experimental group,with 39 patients in both groups.The control group received supportive treatment for advanced malignant tumors,and the experimental group was treated with icotinib hydrochloride on the basis of the control group.The treatment effects and the recovery of functional status after treatment,the safety of treatment and the survival of the two groups were compared.Results After treatment,the KPS score(76.9±2.7)points of the experimental group was higher than that of the control group(43.5±6.8)points,the difference was statistically significant(t=25.400,P<0.05);the treatment effective rate(30.76%)and condition of the experimental group of control rate(84.61%)was higher than the control group(12.82%,51.28%),the difference was statistically significant(χ^2=4.875,9.704,P<0.05);the control group had fever,rash,gastrointestinal symptoms,and elevated transaminase high incidence of adverse symptoms were not significantly different from the experimental group,the difference was not statistically significant(χ^2=0.425,0.245,0.487,0.787,P>0.05);the experimental group has a progression-free survival(7.2±0.5)months and overall survival(10.5±0.7)months were longer than the control group,the difference was statistically significant(t=8.345,7.678,P<0.05).Conclusion Icotinib hydrochloride plays an important role in the treatment of advanced non-small cell lung cancer.It can improve the patient’s KSP score,improve the treatment efficiency,and effectively control the patient’s condition.At the same time,the treatment safety is relatively high,and the patient’s survival after treatment becomes longer.